Chronic Obstructive Plumonary Disease (COPD) research hub

A single group treatment, phase 4, study to assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on physical capacity of males and females aged 18 and 64 years suffering from Chronic Obstructive Pulmonary Disease (COPD)

This study looks at how a nose spray (Otrivin) might help people with a lung condition called COPD. It checks if using the spray can improve how far they can walk, aiming to make breathing and activity easier.